Role of interleukin 10 in norfloxacin prevention of luminal free endotoxin translocation in mice with cirrhosis

Journal of Hepatology

Volumn 61, Issue 4, 2014, Pages 799-808

  Gómez Hurtado, Isabel ^a,b   Moratalla, Alba ^a,b   Moya Pérez, Ángela ^c   Peiró, Gloria ^b   Zapater, Pedro ^a,b   González Navajas, José M ^a,b   Giménez, Paula ^a   Such, José ^a,d   Sanz, Yolanda ^c   Francés, Rubén ^a,b,d  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c INSTITUTO DE AGROQUÍMICA Y TECNOLOGÍA DE ALIMENTOS CSIC   (Spain)

^d MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Cirrhosis; Endotoxin; Interleukin 10; Norfloxacin

Indexed keywords

CARBON TETRACHLORIDE; ENDOTOXIN; INTERLEUKIN 10; NORFLOXACIN; PLACEBO; TOLL LIKE RECEPTOR 4; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL TRANSLOCATION; BILE DUCT LIGATION; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; FLUOROMETRY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTESTINE MUCOSA PERMEABILITY; KLEBSIELLA PNEUMONIAE; LIVER CIRRHOSIS; MESENTERY LYMPH NODE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE MOUSE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DRUG EFFECTS; EXPERIMENTAL LIVER CIRRHOSIS; IMMUNOLOGY; INTESTINE; METABOLISM; MICROBIOLOGY; PERMEABILITY; PHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL TRANSLOCATION; ENDOTOXINS; ESCHERICHIA COLI; INFLAMMATION; INTERLEUKIN-10; INTESTINES; KLEBSIELLA PNEUMONIAE; LIVER CIRRHOSIS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NORFLOXACIN; PERMEABILITY; TOLL-LIKE RECEPTOR 4; TREATMENT OUTCOME;

EID: 84938942655     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.06.028     Document Type: Editorial

References (27)

1. Berg RD. Bacterial translocation from the gastrointestinal tract. J Med 1992; 23: 217-244.
2. Frances R, Zapater P, Gonzalez-Navajas JM, Munoz C, Cano R, Moreu R, et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 2008; 47: 978-985.
3. Bellot P, Garcia-Pagan JC, Frances R, Abraldes G, Gonzalez-Navajas JM, Perez- Mateo M, et al. Translocation of bacterial DNA is associated with worsening of the hyperkinetic systemic circulation and of intrahepatic endothelial dysfunction in patients with cirrhosis and ascites. J Hepatol 2009; 50: S41.
4. Albillos A, de La HA, Gonzalez M, Moya JL, Calleja JL, Monserrat J, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37: 208-217.
5. Albillos A, de la Hera A, Alvarez-Mon M. Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet 2004; 363: 1608-1610.
6. Zapater P, Frances R, Gonzalez-Navajas JM, de la Hoz MA, Moreu R, Pascual S, et al. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology 2008; 48: 1924-1931.
7. Soriano G, Guarner C, Tomas A, Villanueva C, Torras X, Gonzalez D, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992; 103: 1267-1272.
8. Gines P, Rimola A, Planas R, Vargas V, Marco F, Almela M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12: 716-724.
9. Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-824.
10. Zapater P, Cano R, Llanos L, Ruiz-Alcaraz AJ, Pascual S, Barquero C, et al. Norfloxacin modulates the inflammatory response and directly affects neutrophils in patients with decompensated cirrhosis. Gastroenterology 2009; 137: 1669-1679.
11. Li X, Schwacha MG, Chaudry IH, Choudhry MA. Heme oxygenase-1 protects against neutrophil-mediated intestinal damage by down-regulation of neutrophil p47phox and p67phox activity and O2-production in a twohit model of alcohol intoxication and burn injury. J Immunol 2008; 180: 6933-6940.
12. Mandal P, Park PH, McMullen MR, Pratt BT, Nagy LE. The anti-inflammatory effects of adiponectin are mediated via a heme oxygenase-1-dependent pathway in rat Kupffer cells. Hepatology 2010; 51: 1420-1429.
13. Gomez-Hurtado I, Zapater P, Bellot P, Pascual S, Perez-Mateo M, Such J, et al. Interleukin-10-mediated heme oxygenase 1-induced underlying mechanism in inflammatory down-regulation by norfloxacin in cirrhosis. Hepatology 2011; 53: 935-944.
14. Gomez-Hurtado I, Santacruz A, Peiro G, Zapater P, Gutierrez A, Perez-Mateo M, et al. Gut microbiota dysbiosis is associated with inflammation and bacterial translocation in mice with CCl4-induced fibrosis. PLoS One 2011; 6: e23037.
15. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-1332.
16. Such J, Frances R, Munoz C, Zapater P, Casellas JA, Cifuentes A, et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 2002; 36: 135-141.
17. Guarner C, Gonzalez-Navajas JM, Sanchez E, Soriano G, Frances R, Chiva M, et al. The detection of bacterial DNA in blood of rats with CCl(4)-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology 2006; 44: 633-639.
18. Munoz L, Jose BM, Ubeda M, Lario M, Diaz D, Frances R, et al. Interaction between intestinal dendritic cells and bacteria translocated from the gut in rats with cirrhosis. Hepatology 2012; 56(5): 1861-1869.
19. Ishak K, Baptista A, Bianchi L, Callea F, De GJ, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
20. Hartmann P, Haimerl M, Mazagova M, Brenner DA, Schnabl B. Toll-like receptor 2-mediated intestinal injury and enteric tumor necrosis factor receptor I contribute to liver fibrosis in mice. Gastroenterology 2012; 143: e1331.
21. Madsen KL, Malfair D, Gray D, Doyle JS, Jewell LD, Fedorak RN. Interleukin- 10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis 1999; 5: 262-270.
22. Lee C, Ronald AR. Norfloxacin: its potential in clinical practice. Am J Med 1987; 82: 27-34.
23. Wolfson JS, Hooper DC. Norfloxacin: a new targeted fluoroquinolone antimicrobial agent. Ann Intern Med 1988; 108: 238-251.
24. Vrancic M, Banjanac M, Nujic K, Bosnar M, Murati T, Munic V, et al. Azithromycin distinctively modulates classical activation of human monocytes in vitro. Br J Pharmacol 2012; 165: 1348-1360.
25. Kuwata H, Watanabe Y, Miyoshi H, Yamamoto M, Kaisho T, Takeda K, et al. IL-10-inducible Bcl-3 negatively regulates LPS-induced TNF-alpha production in macrophages. Blood 2003; 102: 4123-4129.
26. Sydora BC, Tavernini MM, Wessler A, Jewell LD, Fedorak RN. Lack of interleukin-10 leads to intestinal inflammation, independent of the time at which luminal microbial colonization occurs. Inflamm Bowel Dis 2003; 9: 87-97.
27. Louis H, Van Laethem JL, Wu W, Quertinmont E, Degraef C, Van den BK, et al. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. Hepatology 1998; 28: 1607-1615.